IL10 and neoplasm: We differentiated these BMDMs for 6 days toward a pro-tumor (M2) phenotype using M-CSF, interleukin-4 (IL-4), and IL-10 (Mia et al., 2014) and examined the effect of olaparib on these M2 macrophages (Figure S2A).